Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world’s largest mutual fundExpands market presence across the S&P Total Market Index, covering virtually all U.S.-listed equities, and the S&P Completion Index, which represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500®Continues a series of index inclusions across the U.S. equity benchmark landscape, reflecting ...

Finding a quality mid-cap stock to invest in can lead to huge returns for investors down the road. These are the types of companies that are still in their early growth stages and that can possess significant upside. There is some unavoidable risk and uncertainty, and the key is to ensure you don't take on too much. One stock that's been on my watch list for a while is CRISPR Therapeutics (NASDAQ: CRSP). The company has an intriguing business, as not only could it generate a lot of revenue in the future, ...

Since the beginning of 2026, shares of CRISPR Therapeutics (CRSP) are down by about 11%. While that’s not a great start to the year, there are plenty of reasons to be bullish. For one, Cathie Wood can't get enough of CRSP stock, recently picking up another 438,000 shares across the ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG). On top of that, oversold shares are just starting to pivot from double-bottom support. www.barchart.com Analysts at Piper Sandler just raised the price target on ...

FTSE 10010,410.00 +0.60% Nikkei 22554,313.90 -0.41% Stock Market Live March 17, 2026: S&P 500 (SPY) Flat as Oil Gushes Higher From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here - 24/7 Wall St. S&P 5006,726.10 +0.28% Dow Jones47,021.00 +0.18% Nasdaq 10024,789.20 +0.43% Russell 20002,513.87 +0.38% Investing From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here By Joel SouthPublished Mar 17, 12:16PM EDT Quick Read CRISPR Therapeutics (CRSP) holds $2.56B in p ...

Group 1 - Crispr Therapeutics Ag (NASDAQ:CRSP) has seen a 16% increase in share price over the past 12 months, with ARK Investment increasing its stake by 8% in Q4, resulting in a $10.5 million position [1] - The company holds a first-mover advantage in the gene editing and gene therapy sectors, with its CRISPR-based treatment already approved by the FDA [2] - Crispr's CASGEVY therapy for severe sickle cell disease and beta-thalassemia is generating revenue through a partnership with Vertex Pharmaceuticals [2] Group 2 - Hedge fund sentiment towards Crispr Therapeutics increased in Q4, with 32 funds holding the stock, up from 31 in the previous quarter [3] - The FDA approved Crispr's CRISPR-Cas9 gene editing therapy for sickle cell disease in December 2023, after nearly six years of clinical trials [3] - The therapy, Casgevy, disrupts the BCL11A gene to promote the production of fetal hemoglobin, providing a functional cure for sickle cell disease, which affects approximately 1 in 365 Black or African American births [3] - The treatment costs about $2.2 million per use but is expected to be a one-time treatment, with potential lifetime healthcare savings estimated between $4 million and $6 million [3] - Crispr retains 40% of profits from the partnership with Vertex, which has invested nearly $1.1 billion to increase its stake in the commercialization of Casgevy [3]

Financial Performance - CRISPR Therapeutics reported total revenue of $116 million for FY2025, with $54 million generated in Q4 alone, driven by a nearly threefold increase in patient initiations compared to the previous year [1][6] - A total of 147 patients have started treatment for sickle cell disease or beta thalassemia, supported by expanded reimbursement access across the US, Europe, and the Middle East [1] Product Development - The company is advancing a diverse 'in vivo' liver editing portfolio using lipid nanoparticles, with key programs including CTX310 for cardiovascular conditions and CTX460 for alpha-1 antitrypsin deficiency, expected to enter clinical trials in mid-2026 [2] - CRISPR is collaborating with Sirius Therapeutics on siRNA-based programs targeting thromboembolic diseases, with Phase 2 data for their lead Factor XI candidate expected in H2 2026 [3] - The clinical pipeline includes 'zugo-cel,' a CAR-T cell therapy for autoimmune diseases and B-cell cancers, and CTX213, an islet cell replacement candidate for Type 1 diabetes showing promising preclinical efficacy [3] Technology and Innovation - CRISPR Therapeutics utilizes its Cas9 platform to develop gene-based medicines for serious human diseases [4]

Core Viewpoint - CRISPR Therapeutics AG has announced a private offering of $550 million in convertible senior notes due 2031, which was upsized from a previously announced $350 million offering [1][7] Group 1: Offering Details - The offering is targeted at qualified institutional buyers under Rule 144A of the Securities Act [1] - The notes will have an effective coupon of 1.125%, increased to 1.7308% due to anticipated Swiss tax withholding [2] - Interest payments will be made semiannually starting September 1, 2026, with maturity on March 1, 2031 [2] Group 2: Conversion and Redemption - Holders can convert their notes into common shares at a conversion rate of 13.0617 shares per $1,000 principal amount, equating to an initial conversion price of approximately $76.56 per share [3][4] - The conversion price represents a 45% premium over the last reported sale price of $52.80 per share on March 10, 2026 [4] - The company may redeem the notes starting March 6, 2029, under specific conditions related to the stock price [5] Group 3: Financial Proceeds and Use - The estimated net proceeds from the offering are approximately $536.3 million, or $585.2 million if the option for additional notes is fully exercised [7] - The proceeds will be used for general corporate purposes [7] Group 4: Company Overview - CRISPR Therapeutics is a leading biopharmaceutical company focused on gene-based medicines for serious diseases, with a notable achievement being the approval of CASGEVY, the first CRISPR-based therapy [10] - The company is advancing a diversified pipeline across various therapeutic areas and has established strategic collaborations with major biopharmaceutical partners [10]

Core Viewpoint - CRISPR Therapeutics' stock fell over 12% due to the announcement of new debt issuance, which may dilute existing shareholders' stakes [1][4]. Group 1: Fundraising Details - The company plans to sell $350 million in convertible notes for general corporate purposes, with an option for buyers to purchase an additional $52.5 million [2]. - The notes will mature in early 2031 unless redeemed, repurchased, or converted into common stock [2]. Group 2: Financial Context - CRISPR's current market capitalization is $5.0 billion, with $347.6 million in cash and cash equivalents at the end of last year [3]. - The company has total liabilities of $343.4 million, including $149 million in current liabilities, and burned through $345 million last year for drug development [3]. Group 3: Market Reaction and Future Outlook - The market's negative response to the fundraising announcement is not surprising, as it reflects the typical behavior of biotech startups raising capital [4]. - Despite the setback, the situation does not eliminate the bullish argument for potential investors, as it may present a wider window of opportunity [6].

Core Viewpoint - CRISPR Therapeutics plans to issue $350 million in convertible senior notes due 2031 to qualified institutional investors, with an option for an additional $52.5 million [1][2]. Group 1: Convertible Note Offering - The notes will be sold under Rule 144A of the Securities Act, allowing sales to institutional buyers without public registration [2]. - The debt instruments will rank as senior unsecured obligations, with interest payments occurring biannually [2]. - Payments will start on September 1, 2026, and the securities will mature on March 1, 2031 [3]. Group 2: Conversion Terms - Investors can convert the notes into common shares before maturity under specified conditions, with shares having a nominal value of CHF0.03 ($0.039) [3]. - The coupon rate and conversion terms will be determined at the time of pricing, which will depend on market conditions [3]. Group 3: Use of Proceeds - Proceeds from the sale will be allocated toward general corporate purposes, although specific spending priorities were not outlined [4]. - CRISPR Therapeutics focuses on developing gene-editing therapies using CRISPR/Cas9 technology, targeting blood disorders, oncology, and other severe diseases [4]. Group 4: Recent Earnings Results - The company's gene-editing therapy, Casgevy, generated $54 million in revenue for the fourth quarter and $116 million for the full year [5]. - At the time of publication, CRISPR Therapeutics shares were down 8.54% at $53.75 [5].

Core Insights - CRISPR Therapeutics AG (NASDAQ:CRSP) is recognized as one of the 10 most shorted biotech stocks to consider for investment by hedge funds [1] - Morgan Stanley raised its price target for CRISPR Therapeutics from $32 to $33 while maintaining an Underweight rating [1] - Needham increased its price target from $80 to $82, maintaining a Buy rating, indicating over 45% upside potential [2] Financial Performance - Casgevy, a therapy developed by CRISPR's partner Vertex Pharmaceuticals, generated $116 million in sales in 2025, exceeding the previous target of approximately $100 million [2] - The strong sales performance of Casgevy indicates early commercial traction and supports a positive outlook for CRISPR Therapeutics [2] Company Overview - CRISPR Therapeutics is a gene editing company focused on developing potentially curative medicines for serious diseases, including sickle cell disease and blood disorders [3] - The company's broader pipeline also addresses cancer, autoimmune conditions, and diabetes, positioning it as a leader in the future of genetic medicine [3]